What Is Vma? Normal vs Optimal Range Explained

VMA is the end-stage metabolite of catecholamines—norepinephrine and epinephrine pass through COMT (catechol-O-methyltransferase) and MAO (monoamine oxidase) before arriving at vanillylmandelic acid, which is excreted in urine. The CTD maps over 340 chemical-gene interactions involving catecholamine metabolism genes (DBH, COMT, MAOA, MAOB), illustrating how many medications and dietary compounds alter the pathway that produces VMA. Laboratory reference ranges vary significantly between institutions, but values above 4.5 mmol/mol creatinine—while still considered normal by many labs—indicate the adrenal glands and sympathetic nervous system are producing more catecholamines than a resting, well-regulated system should. The optimal range of 1.0–4.5 reflects balanced sympathetic tone without chronic stress-driven overproduction, while values markedly above normal trigger workup for catecholamine-secreting tumors. Understanding where your VMA falls within this range provides a window into how actively your sympathetic nervous system is firing at baseline.

PubMed indexes over 7,800 publications on VMA testing, predominantly in the context of pheochromocytoma and neuroblastoma screening. A pheochromocytoma—a rare adrenal tumor that secretes catecholamines—typically produces VMA levels two to three times the upper limit of normal, causing episodic hypertension, headaches, sweating, and palpitations. But the more common clinical scenario is moderately elevated VMA from chronic sympathetic overdrive: sustained psychological stress, sleep deprivation, chronic pain, and untreated anxiety all elevate baseline catecholamine production, raising VMA proportionally. FAERS documents catecholamine-related adverse events associated with stimulant medications (amphetamine, methylphenidate) and sympathomimetic decongestants, both of which directly increase norepinephrine and epinephrine levels and therefore VMA. Distinguishing medication-driven VMA elevation from stress-driven or tumor-driven elevation requires careful review of the patient's medication list before interpreting results.

Low VMA carries its own clinical significance. Values below 1.0 mmol/mol creatinine may indicate adrenal insufficiency, where the adrenal glands cannot produce adequate catecholamines for normal stress responses. Dopamine beta-hydroxylase (DBH) deficiency—a rare but important condition—blocks the conversion of dopamine to norepinephrine, producing very low VMA with elevated dopamine metabolites. DBH requires vitamin C and copper as cofactors, so deficiency in either nutrient can impair catecholamine synthesis and reduce VMA. The clinical picture of low VMA includes orthostatic hypotension (feeling dizzy when standing), fatigue, poor exercise tolerance, and impaired stress response. Interpreting VMA always requires context—a single elevated VMA during acute illness or physical stress means something very different from a persistently elevated VMA in a resting, fasting state. Repeat testing under controlled conditions, with dietary restrictions observed and medications accounted for, provides the most reliable assessment of true baseline catecholamine metabolism.